Current treatment of follicular non-Hodgkin's lymphoma

European Journal of Cancer

Volumn 38, Issue 9, 2002, Pages 1167-1172

  Reiser, M ^a   Diehl, V ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Follicular lymphoma; Interferon; Monoclonal antibodies; Radioimmunoconjugates; Transplantation; Treatment

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; IDARUBICIN; INTERFERON; IODINE 131; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; PURINE NUCLEOSIDE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90;

AGE; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CYTOTOXICITY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SPLEEN DISEASE; STEM CELL TRANSPLANTATION;

EID: 0036270041     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00087-4     Document Type: Article

References (44)

1. Cancer statistics, 2001
2. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
4. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997
5. Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group)
6. Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic
7. Long-term results with radiotherapy for stage I-II follicular lymphomas
8. Treatment of non-Hodgkin lymphoma
9. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
10. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series
11. Follicular lymphoma: Have we made any progress?
12. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte
13. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
14. Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia
15. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma
16. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone
17. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group
18. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
19. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma
20. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma
21. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
22. Clinical experience with fludarabine in hemato-oncology
23. Fludarabine phosphate in lymphoma: An important new therapeutic agent
24. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas
25. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) - 2 h infusion for 5 days - As first-line treatment for advanced low grade non-Hodgkin's lymphoma
26. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study
27. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and and long-term follow-up - A report from the Eastern Cooperative Oncology Group
28. Low-grade non-Hodgkin's lymphoma - Development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND)
29. Purine nucleoside analogs in indolent non-Hodgkin's lymphoma
30. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma
31. Interferon alfa for the treatment of follicular lymphomas
32. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial
33. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue - A highly effective regimen for patients with refractory or relapsed indolent lymphoma
34. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma
35. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
36. Allogeneic bone marrow transplantation for low-grade lymphoma
37. Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies
38. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
39. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
40. Principles of radioimmunotherapy for hematologists and oncologists
41. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
42. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
43. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group